Scientists are examining dozens of drugs as possible treatments for coronavirus. But the fortunes of one — Gilead’s remdesivir — has moved global financial markets.
As investors try to parse conflicting scientific evidence about remdesivir’s potential, here are some of the facts:
What
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```